| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 02/16/2006 | US20060035358 Nucleotide sequence encoding a protein that regulates an enzyme involved in the production of reactive oxygen intermediates that affect cell division; determining the activity of drugs that affect the biological activity of these proteins |
| 02/16/2006 | US20060035347 Polynucleotides encoding polypeptides involved in amino acid biosynthesis in Methylophilus methylotrophus |
| 02/16/2006 | US20060035340 Fermenting an appropriate microorganism using glucose as a carbon source and operating two chromatographic separation steps wherein ion exchange chromatography is followed by hydrophobic interaction chromatography, wherein the diphtheria toxin has a purity of at least 98%. |
| 02/16/2006 | US20060035337 Leukocyte adhesion inhibitor-1 polypeptide for use in the treatment of cancer, tumors, chronic infections, leukemia, T-cell mediated auto-immune diseases, parasitic infections, psoriasis, asthma, allergy, to regulate hematopoiesis, to stimulate growth factor activity, to inhibit angiogenesis |
| 02/16/2006 | US20060035335 Use of HCV proteins |
| 02/16/2006 | US20060035332 Novel RFRP-3 and DNA thereof |
| 02/16/2006 | US20060035331 G-protein coupled receptors |
| 02/16/2006 | US20060035329 Human hairless gene and protein |
| 02/16/2006 | US20060035328 Artery-and vein-specific proteins and uses therefor |
| 02/16/2006 | US20060035327 with changed spatial configuration and improved efficacy; preventing or treating viral diseases; antitumor agents; also an artificial gene which codes for the interferon |
| 02/16/2006 | US20060035326 Genes |
| 02/16/2006 | US20060035325 Regulated apoptosis |
| 02/16/2006 | US20060035322 T-cell epitopes in erythropoietin |
| 02/16/2006 | US20060035318 Teneurin c-terminal associated peptides (tcap) and uses thereof |
| 02/16/2006 | US20060035315 Transporters and ion channels |
| 02/16/2006 | US20060035305 Synthetic peptides, conjugation reagents and methods |
| 02/16/2006 | US20060035303 JNK3 modulators and methods of use |
| 02/16/2006 | US20060035299 Method for treatment of indwelling catheter occlusion using fibrinolytic metalloproteinases |
| 02/16/2006 | US20060035293 Antibodies, polypeptides and polynucleotides, used for detection, prevention and treatment of diseases caused by gramnegative bacteria |
| 02/16/2006 | US20060035285 Method for identifying modulators of human orexin-2 receptor |
| 02/16/2006 | US20060035278 Methods and compositions for modulating HGF/Met |
| 02/16/2006 | US20060035268 Methods and compositions for identifying morphogenic protein analogs using morphogenic protein responsive inhibitory elements |
| 02/16/2006 | US20060035263 DRG11-responsive (DRAGON) gene family |
| 02/16/2006 | US20060035260 Nucleotide sequences derived from the genome of retroviruses of the HIV-1, HIV-2 and SIV type, and their uses in particular for the amplification of the genomes of these retroviruses and for the in vitro diagnosis of the diseases due to these viruses |
| 02/16/2006 | US20060035230 Bacterial effector proteins which inhibit programmed cell death |
| 02/16/2006 | US20060035213 POSH nucleic acids, polypeptides and related methods |
| 02/16/2006 | US20060035209 Screening method |
| 02/16/2006 | US20060034946 Irrigating solution for neurosurgical procedures |
| 02/16/2006 | US20060034941 Organ preconditioning, arrest, protection, preservation and recovery |
| 02/16/2006 | US20060034938 Therapeutic mixture comprising antisense agents, chemotherapeutic compounds and bile extract for use in treatment of cell proliferative disorders |
| 02/16/2006 | US20060034935 Compositions and methods for treating excessive bleeding |
| 02/16/2006 | US20060034932 Anti-angiogenic compositions and methods of use |
| 02/16/2006 | US20060034920 Effervescent formulations of oxytocin |
| 02/16/2006 | US20060034903 Apparatus and method for transdermal delivery of natriuretic peptides |
| 02/16/2006 | US20060034892 Composition for topical administration |
| 02/16/2006 | US20060034866 Adipocyte complement related protein homolog zacrp3 |
| 02/16/2006 | US20060034864 Compounds, compositions and methods for the endocytic presentation of immunosuppressive factors |
| 02/16/2006 | US20060034863 Compositions useful as ligands for the formyl peptide receptor like 1 receptor and methods of use thereof |
| 02/16/2006 | US20060034860 Protein-protein interactions in human immunodeficiency virus |
| 02/16/2006 | US20060034858 A beta or an immunogenic fragment thereof presented by a virus or bacteria as part of an immunogenic composition effective to induce an immunogenic response comprising antibodies against A beta |
| 02/16/2006 | US20060034857 Administering an isolated polynucleotide encoding a Notch ligand comprising a Delta Serrate Ligand (DSL) domain to a cell of a patient; the Notch ligand is expressed and interacts with a Notch receptor to reduce T-cell activation; antiallergens; graft rejection; autoimmune disease |
| 02/16/2006 | US20060034852 Comprising transmembrane activator and calcium modulator and cyclophilin ligand-interactor (TACI) receptor moiety and an immunoglobulin moiety comprising a heavy chain constant region of an immunoglobulin; interfere with binding of a tumor necrosis factor receptor with its ligand; antitumor agents |
| 02/16/2006 | US20060034851 Targeted therapeutic delivery of vitamin D compounds |
| 02/16/2006 | US20060034848 Methods and compositions for treating Alzheimer's disease |
| 02/16/2006 | US20060034847 Methods of treating a subject for a condition |
| 02/16/2006 | US20060034846 Use of TF antagonists |
| 02/16/2006 | US20060034844 Stimulation of T cells against self antigens using CTLA-4 blocking agents |
| 02/16/2006 | US20060034843 Interaction of Smad6 with Hox proteins and uses thereof |
| 02/16/2006 | US20060034838 Anti-human VEGF receptor Flt-1 monoclonal antibody |
| 02/16/2006 | US20060034834 Intrabody-mediated control of immune reactions |
| 02/16/2006 | US20060034831 Combination therapy for diabetes, obesity and cardiovascular diseases using GDF-8 inhibitors |
| 02/16/2006 | US20060034826 contacting an immune cell with an agent that modulates the interaction between PD-1 and a PD-1 ligand (e.g., soluble forms of PD-1 or PD-1 ligand or antibodies to PD-1); inhibits signaling via PD-1 |
| 02/16/2006 | US20060034824 Pharmaceutical composition comprising carriers for products |
| 02/16/2006 | US20060034823 Method of production and use of crotoxin as an analgesic |
| 02/16/2006 | US20060034822 Hyaluronidase preparation for ophthalmic administration and enzymatic methods for accelerating clearance of hemorrhagic blood from the vitreous body of the eye |
| 02/16/2006 | US20060034821 periodically administering neuraminidase to a lukemia patient |
| 02/16/2006 | US20060034820 Administering a lactoferrin, a lysozyme, defensin (EP2E) to treat microbial infections (Hemophilus influenzae strain 12, Moraxella catarrhalis, or Streptococcus pneumoniae serotype 3 or serotype); labyrinthitis and meningitis |
| 02/16/2006 | US20060034819 Proteins and methods useful for assessing risk of cardiovascular disease |
| 02/16/2006 | US20060034818 Placental alkaline phosphatase to control diabetes |
| 02/16/2006 | US20060034817 Cloning, overexpression and therapeutic use of bioactive histidine ammonia lyase |
| 02/16/2006 | US20060034816 comprises oxidoreductase enzyme in hydrated condition that catalyses conversion of atmospheric oxygen to hydrogen peroxide for transmittal through the dressing to the skin |
| 02/16/2006 | US20060034815 Novel statin pharmaceutical compositions and related methods of treatment |
| 02/16/2006 | US20060034811 Melanoma vaccine and methods of making and using same |
| 02/16/2006 | US20060034804 Adenoviral vectors having a protein IX deletion |
| 02/16/2006 | US20060034801 Method for treating or preventing ischemia reperfusion injury or multi-organ failure |
| 02/16/2006 | US20060034800 Method for treatment of drug addiction and for screening of pharmaceutical agents therefor |
| 02/16/2006 | US20060034799 Tissue protective cytokines for the protection, restoration, and enhancement fo responsive cells, tissues and organs |
| 02/16/2006 | US20060034764 Fusion proteins of mycobacterium tuberculosis antigens and their uses |
| 02/16/2006 | DE4229526B4 Vorrichtung zur Aufnahme und zum Einbringen von biologisch aktiven Geweben oder Zellen in den menschlichen Körper Device for receiving and for introducing biologically active tissues or cells in the human body |
| 02/16/2006 | DE19641213B4 Cyclische Peptide, Verfahren zu ihrer Herstellung und ihre Verwendung Cyclic peptides, process for their preparation and their use |
| 02/16/2006 | DE102004034380A1 Use of a composition comprising a TRAIL protein and an indole or benzimidazole derivative to prepare a medicament for treating pain |
| 02/16/2006 | CA2589765A1 Compounds for proteasome enzyme inhibition |
| 02/16/2006 | CA2584970A1 Method for the treatment of mammalian skin tissues via pulse irradiation in the presence of a photoactive compound |
| 02/16/2006 | CA2576193A1 Taj in neuronal function |
| 02/16/2006 | CA2575830A1 Rage fusion proteins and methods of use |
| 02/16/2006 | CA2575617A1 Lysis/resealing process and device for incorporating an active ingredient in erythrocytes |
| 02/16/2006 | CA2575406A1 Treatment of hyperproliferative disease with superantigens in combination with another anticancer agent |
| 02/16/2006 | CA2575123A1 Peptide sequence for modulation of delta protein kinase c |
| 02/16/2006 | CA2573856A1 Antidiabetic oral insulin-biguanide combination |
| 02/16/2006 | CA2573811A1 Stable particle formulations of erythropoietin receptor agonists |
| 02/16/2006 | CA2573810A1 Stable suspension formulations of erythropoietin receptor agonists |
| 02/16/2006 | CA2573512A1 Compositions for delivering peptide yy and pyy agonists |
| 02/16/2006 | CA2573368A1 Improved aprotinin variants |
| 02/16/2006 | CA2572868A1 Long-acting colloidal insulin formulation and preparation thereof |
| 02/16/2006 | CA2571407A1 Amino acid derived prodrugs of propofol, compositions and uses thereof |
| 02/16/2006 | CA2570324A1 Rage fusion proteins and methods of use |
| 02/16/2006 | CA2514438A1 Process for the preparation of a von willebrand factor (vwf) concentrate by chromotographic means and vwf prepared thereby |
| 02/15/2006 | EP1626096A2 In vitro method of detecting a cell proliferative disorder involving fibroblast growth factor homologous factor-1 (FHF-1) |
| 02/15/2006 | EP1626055A2 Non-mammalian GnRH analogs and uses thereof in the regulation of the immune system |
| 02/15/2006 | EP1626054A1 Oligopeptide |
| 02/15/2006 | EP1625870A2 Needle for intradermal delivery of substances having penetration limiting means |
| 02/15/2006 | EP1625858A1 Compounds for treating ischemic tissue |
| 02/15/2006 | EP1625853A1 Apoptosis inducer for cancer cell |
| 02/15/2006 | EP1625395A1 Method for identifying tff2 regulating agents and agents identified using said method |
| 02/15/2006 | EP1625202A2 Novel lipolytic enzyme lip1 |
| 02/15/2006 | EP1625159A1 Materials and methods relating to g-protein coupled receptor oligomers |
| 02/15/2006 | EP1625158A2 Peptides for use in treating obesity |
| 02/15/2006 | EP1625157A2 Immunogenic human tnf alpha analogues with reduced cytotoxicity and methods of their preparation |
| 02/15/2006 | EP1625156A2 Peptides that bind to the erythropoietin receptor |
| 02/15/2006 | EP1625155A1 Novel antimicrobial peptides with heparin binding activity |